-
Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
J Virol. 2000 Jan;74(1):254-63
PMID: 10590113
-
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
J Virol. 1995 Jul;69(7):4413-22
PMID: 7769703
-
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
AIDS. 1999;13 Suppl A:S137-62
PMID: 10885772
-
Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate.
J Virol. 2000 Oct;74(20):9749-54
PMID: 11000249
-
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
J Virol. 1995 Sep;69(9):5723-33
PMID: 7543586
-
Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.
J Virol. 1995 Oct;69(10):6191-8
PMID: 7545244
-
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
J Infect Dis. 1996 Feb;173(2):340-8
PMID: 8568294
-
Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
J Virol. 1997 Apr;71(4):2779-85
PMID: 9060632
-
Core structure of gp41 from the HIV envelope glycoprotein.
Cell. 1997 Apr 18;89(2):263-73
PMID: 9108481
-
Atomic structure of the ectodomain from HIV-1 gp41.
Nature. 1997 May 22;387(6631):426-30
PMID: 9163431
-
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
J Infect Dis. 1998 Feb;177(2):310-9
PMID: 9466516
-
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
Nature. 1998 Jun 18;393(6686):648-59
PMID: 9641677
-
Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
J Virol. 1998 Aug;72(8):6332-8
PMID: 9658072
-
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
AIDS. 1998 Dec 24;12(18):2407-15
PMID: 9875578
-
Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
J Virol. 1999 Jul;73(7):5294-300
PMID: 10364275
-
Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.
J Virol. 1999 Oct;73(10):8873-9
PMID: 10482646
-
Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.
J Virol. 2000 Dec;74(24):11955-62
PMID: 11090196
-
Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564.
Antimicrob Agents Chemother. 2001 Jan;45(1):60-6
PMID: 11120945
-
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2019-35
PMID: 11153085
-
Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.
Structure. 2000 Dec 15;8(12):1329-39
PMID: 11188697
-
Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.
J Virol. 2001 Apr;75(7):3435-43
PMID: 11238869
-
Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.
J Virol. 2001 Jun;75(12):5457-64
PMID: 11356952
-
Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.
J Virol. 2001 Jul;75(14):6700-4
PMID: 11413338
-
Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.
J Virol. 1993 Aug;67(8):4785-96
PMID: 7687303
-
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
J Virol. 1994 Aug;68(8):4821-8
PMID: 7518527
-
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
JAMA. 1994 Aug 10;272(6):475-80
PMID: 7913731
-
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
J Virol. 1994 Sep;68(9):6006-13
PMID: 8057475
-
Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120.
Virology. 1995 Feb 1;206(2):878-84
PMID: 7856100
-
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion.
J Virol. 1995 Jun;69(6):3771-7
PMID: 7538176
-
Higher western blot immunoreactivity of glycoprotein 120 from R5 HIV type 1 isolates compared with X4 and X4R5 isolates.
AIDS Res Hum Retroviruses. 2000 May 20;16(8):765-75
PMID: 10826483